Retatrutide RT Series

Retatrutide-High Quality Research Peptides

What is Retatrutide? Overview

Retatrutide (LY3437943), a peptide molecule beyond traditional cognition, is leading the change in the global exploration of metabolic diseases. Retatrutide (LY3437943), a three-target synthetic peptide derived from the modification of natural incretin skeleton, embodies the research and development wisdom of Lilly Laboratory for decades. It does not simply imitate a single hormone in the body, but integrates the regulatory capabilities of three key metabolic signaling pathways through precise molecular design, like a master proficient in many fields, to achieve precise synergy in a complex energy balance network. The stability and activity of this compound are exemplary. Compared with traditional single-target peptides, which are easy to be degraded rapidly, Retatrutide can maintain lasting activity both in vivo and in vitro after special structural modification, and can play a stable role even in complex physiological environment. Researchers have described it as a well-designed ocean-going ship that navigates steadily in the turbulent metabolic ocean, while other similar drugs are as vulnerable to wind and waves as small boats.

Retatrutide Peptide Structure
Amino Acid Sequence: Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-diacid-C20-gamma-Glu-(AEEA)-Lys-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂

A long chain composed of 39 amino acid residues, the arrangement of each unit has been optimized through tens of thousands of experiments. The structure incorporates three unique non-natural amino acids (Aib, α-aminoisobutyric acid), especially the Aib modifications at positions 2, 13, and 20, which act like a "protective shield" for the peptide chain, significantly enhancing its resistance to enzymatic degradation and extending its half-life to 6 days, enabling convenient once-weekly dosing. The amidation modification at the molecule's ends and the side-chain fatty acid modification further optimize receptor affinity and pharmacokinetic properties, allowing this molecule to simultaneously and precisely bind to and activate three receptors: GLP-1, GIP, and glucagon (GCG), achieving a unique "one peptide, three effects" mechanism.

Retatrutide Peptides and Weight Management

In the field of obesity treatment, Retatrutide has demonstrated revolutionary breakthroughs. In the pivotal Phase III TRIUMPH-4 trial, obese patients with a baseline average weight of 112.7 kg achieved an average weight loss of 28.7% (approximately 71.2 lbs) after 68 weeks of treatment with a 12 mg dose, far exceeding the 3%-5% effect of traditional weight-loss drugs and the 15% effect of single-target GLP-1 drugs. This means that a 100 kg obese person can safely lose nearly 30 kg, restoring a near-healthy BMI level.

Its weight loss mechanism covers three core, interconnected steps:
Central appetite suppression: Activates the hypothalamic satiety center, reducing hunger and allowing patients to naturally reduce calorie intake without the need for drastic dieting.
Delayed gastric emptying: Extends food digestion time, enhances post-meal satiety, and prevents overeating.
Peripheral fat burning acceleration: Activates glucagon receptors, promoting fat breakdown and energy consumption while reducing fat synthesis, achieving the dual effect of "eating less and burning more fat."
More remarkably, Retatrutide's weight loss primarily focuses on fat reduction with minimal muscle loss. Patients not only experience weight loss but also a more toned physique and healthier metabolism, completely overcoming the traditional weight loss dilemma of being "thin and frail."

Retatrutide Peptide and Blood Glucose Control

As a peptide developed in the field of diabetes, Retatrutide also exhibits remarkable blood glucose control effects. In patients with type 2 diabetes, it reduces glycated hemoglobin (HbA1c) by up to 2.16%, significantly better than single-target and dual-target drugs. Its unique "glucose-dependent" mode of action—activating insulin secretion only when blood glucose is elevated and ceasing its effect when blood glucose is normal—completely avoids the risk of hypoglycemia, making its safety far superior to traditional hypoglycemic drugs.

Simultaneously, it comprehensively improves insulin resistance, restoring cellular sensitivity to insulin, not only lowering blood glucose but also fundamentally improving the pathological mechanisms of type 2 diabetes. Clinical trials show that over 60% of patients achieve target blood glucose levels after treatment, reducing or eliminating dependence on multiple hypoglycemic drugs.

Retatrutide Peptide and Safety

Currently published Phase I, II, and III clinical trial data show that Retatrutide has a good safety profile, with most adverse reactions being mild to moderate and gradually subsiding with treatment duration:

Common reactions: Gastrointestinal reactions (nausea 25%, diarrhea 18%, vomiting 12%), consistent with GLP-1 inhibitors, mostly occurring during dose escalation.

Special reactions: Mild skin paresthesia (approximately 20% in the 12mg group), mostly transient numbness and tingling, not affecting daily life.

Discontinuation rate: The discontinuation rate due to adverse reactions in the highest dose group was approximately 18%, lower than some similar drugs, and mostly due to excessive efficacy or patient-initiated discontinuation rather than serious side effects.

To date, no serious organ toxicity, cardiovascular risk, or carcinogenic risk signals have been found. Phase I trials in healthy individuals and Phase II trials in obesity and diabetes have been successfully completed, and large-scale Phase III trials continue to validate long-term safety.

Our Retatrutide has the following key features:
* Guaranteed Purity: Each batch is tested by both HPLC and mass spectrometry, ensuring a purity of ≥99%, verified by an independent laboratory.
* Precise Dosage: 5mg vials are ideal for research dosage needs, avoiding waste and facilitating the preparation of different concentrations.
* Stable Dosage Form: Lyophilized powder formulation, can be stored long-term at -20℃, maintaining stable activity without degradation.
* Research-Specific: Strictly adheres to laboratory standards, suitable for cell, animal models, and preclinical studies.

Notice: Retatrutide serves research and educational purposes exclusively. This product has received no FDA evaluation and is not intended to diagnose, treat, cure, or prevent any disease. Human consumption is prohibited. Observe all applicable laws and regulations. Consult qualified researchers before beginning studies.